# RELY-30 (NCT02917083)

> CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

No report yet. It can be ordered.

- Indication: relapsed CD30 expressing lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02917083
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Baylor College of Medicine
- Conditions: Hodgkin's Lymphoma; Non-Hodgkin Lymphoma
- Interventions: CAR T Cells
- Enrollment: 60
- Primary outcome: Number of Patients with Dose-Limiting Toxicities (DLT)

## Indexed commentary on RELY-30 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=rely-30-nct02917083